ABBV

Pharmaceutical company share prices may suffer, but probably not by as much as some might fear.

Yahoo · 8h ago

Chasing the highest dividend yield is exactly how investors end up owning something that quietly eats their principal alive. A six-holding portfolio shows how a much lower yield can generate far more income a decade from now than a double-digit payout ever could.

Yahoo · 1d ago

AbbVie (NYSE:ABBV) acquired a stake in ADARx Pharmaceuticals during its IPO, gaining exposure to RNA interference drug candidates. The investment in ADARx ties AbbVie to RNA-based therapies being developed for certain rare disease indications. Health Canada granted marketing authorization for AbbVie's EPKINLY for adults with relapsed or refractory follicular lymphoma. AbbVie's move into ADARx's IPO and the new EPKINLY approval both need weighing against the rest of our ABBV thesis. We have...

Yahoo · 1d ago

Dividend Kings are underperforming SPY in September, with a -4.22% average return versus SPY's marginal gain.

SeekingAlpha · 1d ago

Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.

Yahoo · 1d ago

InMode (INMD) stays rangebound as US sales slip; global growth and consumables stabilize. Read here for a detailed investment analysis.

SeekingAlpha · 1d ago

AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.

Yahoo · 1d ago